Latamoxef (Moxalactam) is a new oxacephem antibiotic that should prove useful in neonatal treatment. Three characteristics commend it for use in this group of patients-excellent in vitro activity against most potential neonatal pathogens,' lack of serious toxicity, and good cerebrospinal fluid penetration.2 3 The standard treatment for suspected or proved neonatal sepsis is an aminoglycoside (usually gentamicin) and penicillin or ampicillin. Although this combination has been successful, it has several inherent disadvantages: the narrow therapeutic margin and the unpredictability of blood concentrations, especially during the neonatal period, necessitates laboratory monitoring of serum aminoglycoside concentrations;4 problems associated with infection due to gentamicin resistant organisms are reported increasingly among neonates; and the poor penetration of gentamicin into cerebrospinal fluid limits its use in the treatment of neonatal meningitis.5 6 The early signs and symptoms of meningitis in the newborn are vague and non-specific and it usually arises as a complication of septicaemia, sometimes even where this has apparently been appropriately treated. It is desirable therefore that drugs used for the routine treatment of clinical sepsis should pass into the cerebrospinal fluid even when meninges are not inflamed.
The purpose of this study was to assess the safety 34( and usefulness of latamoxef for initial treatment of suspected sepsis in the newborn and to determine its pharmacokinetics in this age group.
Patients
Thirty one neonates with a birthweight of mean (SD) 2-0 (0.83) kg (range 0-68 to 3-97 kg) and a gestational age of 33 (4) weeks (range 27 to 40 weeks) who had clinical evidence suggesting serious infection and who would otherwise have received gentamicin and penicillin were treated with latamoxef (100 mg/kg/day in two divided doses). All except four began treatment during the first week of life and in 22 treatment started during the first three days. Signs and symptoms arousing suspicion of infection in the 31 babies included respiratory problems (26 babies), indicative radiological findings (18) , prolonged rupture of membranes (10) , need for ventilator support (14) , maternal infection (6), maternal pyrexia (four), and general deterioration (three). Most babies had several indications of possible sepsis.
Organisation of the study
Only babies who were judged to require chemotherapy on clinical grounds were admitted to the study. Blood Thirty of 31 data sets had a significant goodness of fit with the computer model. Pharmacokinetic variables after single and multiple injections are shown in Table 3 . In babies of comparable gestational age, postnatal age, and birthweight peak concentrations were higher after multiple injections (Figure) but clearance was more rapid (P<0-02) and half life shorter (P<0.03) resulting in significantly lower trough concentrations (P<0.02) after two to five days' treatment (Table 3) . Serum half life decreased with increasing postnatal age (r =-0-4118, n = 30, P<0.02).
Half life was also shorter (r =-0-3944, n = 29 P<0-05) in babies who were pyrexial. The volume of distribution was significantly larger in babies with respiratory problems, (t28 = 3-3, P<0-005), with low values of serum protein (r = 0-4307, n = 24, P<0-005) and those receiving intravenous treatment Stutman et al, 9 which is contrary to earlier reports by Cashore et al. 10 Concern has been expressed that the new broad spectrum cephalosporins may affect gut flora sufficiently to upset vitamin K production and absorption and hence blood clotting mechanisms. We could find no evidence of this in the present study.
Latamoxef has a relatively low degree of activity against Streptococcus agalactiae (Lancefield group B streptococcus, MIC9, = 4 mg/l). Nevertheless three babies in the study who were infected with this organism responded well and the organism was eradicated probably as a result of the high serum concentrations maintained throughout treatment ( 
